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Summary
Almost all patients (90-100%) who have undergone radiation treatment (RT) of head and neck region develop at least 
one oral complication. Oral complications of head and neck RT can be acute and chronic. Acute complications occur during 
RT and include oral mucositis, dry mouth and taste sensation disorder. Chronic complications occur several weeks, months 
or years after RT cessation, and include radiation caries, osteoradionecrosis and trismus.
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ORALNE KOMPLIKACIJE ZRAČENJA GLAVE I VRATA
Sažetak
Gotovo svi pacijenti (90-100%) koji su podvrgnuti terapijskom zračenju u području glave i vrata razviju neku od 
 komplikacija u usnoj šupljini. Oralne komplikacije terapijskog zračenja glave i vrata mogu biti akutne i kronične. Akutne 
komplikacije nastaju tijekom zračenja i u njih ubrajamo oralni mukozitis, suhoću usta i poremećaj okusne osjetljivosti. Kro-
nične komplikacije nastaju nekoliko tjedana, mjeseci ili godina po završetku zračenja, i podrazumijevaju radijacijski karijes, 
osteoradionekrozu i trizmus.
KLJUČNE RIJEČI: usna šupljina, radioterapija glave i vrata, akutne komplikacije, kronične komplikacije.
* All article fi gures are from archive of Department of Oral 
medicine, School of dental medicine, University of Zagreb.
INTRODUCTION
Oral complications of head and neck irrradi-
ation can be acute and chronic. Acute complica-
tions occur during the radiation treatment (RT) 
and last 3-4 weeks after completion of therapy. 
These complications are result of toxic products 
that arise in irradiated tissue. Acute complications 
are oral mucositis, taste loss and dry mouth. 
Chronic complications develop gradually; weeks, 
months or years after the end of RT, as a result of 
decreased blood supply to the tissue, the forma-
tion of connective tissue and muscle fi brosis, and 
changes in cell number (1). Chronic complications 
are radiation caries, trismus and osteoradionecro-
sis (2).
ACUTE COMPLICATIONS OF HEAD 
AND NECK IRRADIATION
Oral mucositis
The fi rst acute and the most common oral 
complication of head and neck RT is oral mucositis 
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(OM). This mucosal damage develops in 80-90% of 
the patients during the early phase of RT and con-
tinues for 2–3 weeks post treatment period (3). 
Oral mucositis is defi ned as an infl ammation of the 
oral mucosa due to damage of DNA and subse-
quent death of basal keratinocytes. Cli nically, OM 
manifests as ulcerative infl ammation (Figure 1) of 
the mouth associated with pain, dysphagia, odyn-
ophagia and diﬃ  culty speaking which can lead to 
discontinuation of RT. Pathogenesis of OM in-
volves fi ve stages: initiation, activation, signal am-
plifi cation, ulceration and healing. During the ul-
ceration stage, patients develop ulcerations colo-
nized by microorganisms that further promote 
epithelial damage. The healing stage starts when 
DNA is no longer exposed to irradiation (4).
The fi rst clinical sign of OM, which develops 
during the fi rst week of RT, is whitish of oral mu-
cosa. During the third week of RT, patients devel-
op ulcerations covered with fi brinous pseudo-
membranes that are prone to secondary infection. 
The intensity of OM depends on several factors 
related to RT, and they include total dose, frac-
tion size, fi eld size, number and frequency of frac-
tion, and type of ionizing irradiation (3,4). Numer-
ous scoring scales are available for the classifi ca-
tion of OM (5-7), but the most used one is the one 
established by the World Health Organization 
(WHO) (8).
The WHO scoring scale for OM according to 
WHO based on clinical appearance and functional 
status:
• grade 0 (none) = no pain,
• grade 1 (mild) = oral soreness and erythema,
• grade 2 (moderate) = erythema and ulcerations, 
solid diet tolerated,
• grade 3 (severe) = oral ulcers, liquid diet only,
• grade 4 (life-threatening) = oral alimentation 
impossible.
Up till now, there is still no eﬀ ective therapy 
for the prevention of OM in head and neck irradi-
ated patients. The treatment of OM is symptom-
atic, and involves pain management, infection 
prevention and maintaining normal functioning 
of oral cavity (9).
Xerostomia
Xerostomia is one of the most common and 
diﬃ  cult oral complication of RT. It develops in the 
early phase of RT and becomes chronic oral com-
plication due to irreversible irradiation damage of 
salivary glands (Figure 2). Lack of saliva predis-
poses other oral complications such as dental car-
ies, oral infections, dysgeusia, dysphagia, oral 
pain and discomfort (10). Consequently, amount 
of saliva decreases, together with salivary compo-
sition changes. Concentration of diﬀ erent saliva 
ions and proteins increases, while the concentra-
tion of the bicarbonate ion decreases, causing low 
pH and low buﬀ er capacity (11,12). Parotid glands 
mostly produce stimulated, watery saliva and it’s 
serous acinar cells are more radiosensitive than 
mucous cells of submandibular and sublingual 
glands (13). The main etiologic factor for the de-
velopment of xerostomia is irradiation of parotid 
glands, as well as total dose of irradiation (14). Xe-
rostomia becomes chronic oral complication if ra-
diation dose exceeds 40 Gy, which is usually the 
case in the treatment of head and neck tumors, 
when total dose is greater than 60 Gy. In that case, 
salivary production decrease up to 80% (1). It has 
been shown that use of intensity-modulated radi-
ation therapy (IMRT) can reduce the radiation 
dose to salivary glands and decrease symptoms of 
xerostomia (15,16). Changes in saliva seriously af-
fect the quality of life, and salivary glands preser-
vation during RT may reduce long-term salivary 
gland hypofunction. Treatment options implies 
the use of saliva substitutes which are mainly 
based on carboxymethylcellulose (10).
Taste disorder
During RT most of patients develop complete 
or partial taste loss. The preavlence of taste disor-
der in patients receiving RT alone is 66.5%, but 
when it is combined with chemotherapy it goes 
up to 76% (17). Taste disorder occurs as a result of 
direct radiation eﬀ ect on taste buds which are ra-
diosensitive and damaged at doses of 10 Gy (3). 
Except of taste buds damage, taste disorder also 
occurs due to changes in salivary fl ow and compo-
sition. However, most of patients state their taste 
disorder as moderate. Mostly, taste sensation re-
turn to normal within 2-6 months after RT cessa-
tion, and for that reason treatment is not neces-
sary. However, in about 15% of patients, taste dis-
order can last longer, in some cases even after 5-7 
years. To date, there are no recommended preven-
tive and curative actions in this respect (17). Ami-
fostine, zinc gluconate and dietary counseling 
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have been tested for prevention or treatment of RT 
related taste disorder, but with varying success 
(18,19).
CHRONIC COMPLICATIONS OF HEAD 
AND NECK IRRADIATION
Radiation caries
Radiation caries is primarily result of sali-
vary hypofunction, saliva composition changes 
and increase in acidogenic bacteria number. There-
fore, secreted saliva is thick, sticky and viscous fol-
lowed by decrease in pH values and increase in 
the number of acidogenic bacteria - S. mutans, 
 Lactobacillus sp. and Candida sp. (10) These saliva 
changes increase the risk for dental caries and oral 
infections development. Irradiation also has a di-
rect harmful eﬀ ect on dental hard tissue, which 
depends on radiation dose, in case the teeth are 
located in the radiation fi eld. Doses lower than 30 
Gy cause minimal harmful eﬀ ect on hard dental 
tissue, while doses greater than 60 Gy increase 
risk of tooth breakdown 10 times. Usually, radia-
tion caries lesions are located in the cervical re-
gion, and most aﬀ ected teeth are mandibular inci-
sors (Figure 3). These caries lesions are very pro-
gressive and may lead to tooth breakdown in only 
few months (3,12). Despite their progressed clini-
cal presentation, this lesions are painless (20).
The risk of development of radiation caries in 
head and neck irradiated patients is lifelong, 
therefore proper oral hygiene, fl uoride products 
usage and regular dental check-ups (every one to 
Figure 1. Oral mucositis
Figure 2. Xerostomia
Figure 3. Radiation caries
Figure 4. Mandibular osteoradionecrosis
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three months) to avoid the most serious complica-
tion, which is osteoradionecrosis, are extremely 
important.
Osteoradionecrosis
The most serious chronic and irreversible ra-
diation complication is osteoradionecrosis (ORN), 
a consequence of the harmful radiation eﬀ ect on 
the bone. The defi nition of ORN is considered to 
be „exposed bone area without signs of healing 
for at least 3 months and without relapse of the 
underlying disease“ (1). However, there is no uni-
versally accepted ORN defi nition in the literature, 
therefore, prevalence and incidence data of jaw 
ORN are not known. In the literature, relative fre-
quency data ranges from 0-7.1%, but for the pa-
tients with oral cancer it is signifi cantly higher and 
goes up to 13.6% (21). Two-thirds of ORN cases 
localized in the orofacial region are associated 
with some traumatic events such as tooth extrac-
tion, traumas with unadapted prosthesis, biopsy 
and periodontal surgery. For that reason, dental 
extractions must be avoided after RT cessation. In 
case dental extractions are necessary, it is recom-
mended to perform them during the fi rst 5-6 
months after RT. Infl ammation and obliteration of 
the blood vessels that appear after RT, and cause 
hypovascularization with decreased healing abil-
ity, is not process which occurs during one night. 
It takes 5-6 months to develop this degenerative 
processes. These changes are irreversible and pro-
gressive, and risk for ORN development remains 
viable. In one-third of cases ORN can occur spon-
taneously (22,23).
Risk of ORN increases with total radiation 
dose (> 65 Gy), volume of irradiated bone, irradia-
tion mode and additional chemotherapy. Other 
risk factors reported in the literature are poor oral 
hygiene, malnutrition, trauma, smoking, uncon-
trolled diabetes and alcoholism (21,22). The most 
commonly aﬀ ected bone in the orofacial region is 
the mandible (Figure 4). Subjective symptoms of 
ORN are pain, although in the initial stage it can be 
completely painless, taste changes, halitosis, dyses-
thesia and food accumulation in necrotized areas of 
exposed bone. Untreated ORN can lead to the fi s-
tula formation and pathological fractures of the af-
fected bone (24). Management of ORN includes 
conservative treatment, surgical debri dement with 
the use of adjunctives therapies of antibiotics and/
or hyperbaric oxygen (HBO) treatment (25).
Trismus
Trismus or reduced mouth opening is a re-
sult of harmful radiation eﬀ ects on the masticato-
ry muscles and/or temporomandibular joint. It 
develops 3-6 months after RT cessation and very 
often is irreversible. RT causes spasm and fi brosis 
of masticatory muscles leading to reduced mouth 
opening with interincisal space less than 35 mm. 
Not every patient who receives RT of head and 
neck will develop trismus, and the prevalence of 
this condition, reported in the literature, is be-
tween 5-40% (26,27). The severity of trismus varies 
depending on the mode of irradiation, total dose 
of radiation, treatment modality, tumor location 
and physical condition (28,29). In the literature, 
reported data show that a total dose of radiation 
greater than 60 Gy increases the incidence of 
 trismus up to 47% (28). Furthermore, use of IMRT 
decreases the incidence of trismus. Development 
of trismus negatively aﬀ ects quality of life, result-
ing in diﬃ  culties with food intake, speech and 
maintaining oral hygiene (30). It is very important 
to identify early signs of trismus considering the 
fact that early treatment can signifi cantly aﬀ ect its 
prevention. For the prevention as well as for the 
treatment of reduced mouth opening passive and 
active physiotherapy can be performed (31).
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